Condition (MeSH)
Molluscum Contagiosum
ClinicalTrials.gov lists 22 trials for Molluscum Contagiosum or a narrower condition beneath it. Novan, Inc. has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Molluscum Contagiosum itself; the rest are tagged with a narrower condition beneath it.
When did Molluscum Contagiosum trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 2 |
| 2022 | 3 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 4 |
| 2012 | 1 |
| 2010 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Molluscum Contagiosum trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Not applicable | 4 |
| Observational | 1 |
How many Molluscum Contagiosum trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 16 |
| Terminated | 2 |
| Withdrawn | 2 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Molluscum Contagiosum trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novan, Inc. | 4 |
| Verrica Pharmaceuticals Inc. | 3 |
| Laboratoire Dermatologique ACM | 1 |
| The Skin Center Dermatology Group | 1 |
| Veloce BioPharma LLC | 1 |
Which drugs are being tested for Molluscum Contagiosum? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cantharidin | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SB206 12% | 3 |
| Calcium Hydroxide | 2 |
| cantharidin's vehicle | 1 |
| VBP-245 Topical Gel | 1 |
| SB206 10.3% berdazimer | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Molluscum Contagiosum trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 2 | 1 |
| Serious Treatment Emergent Adverse Events | 1 | 1 |
| Supracondylar Fracture of right humerus, closed reduction | 1 | 1 |
Which publications cover Molluscum Contagiosum? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results. | American journal of clinical dermatology | 2023 | Yes |
| Cold atmospheric pressure plasma clears molluscum contagiosum. | Experimental dermatology | 2023 | Yes |
| Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. | JAMA dermatology | 2022 | Yes |
| Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. | American journal of clinical dermatology | 2021 | Yes |
| A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum. | Journal of drugs in dermatology : JDD | 2021 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.